How to buy Smith-and-Nephew SNATS stock (SNN)

Smith-and-Nephew SNATS is a medical devices business based in the US. Smith-and-Nephew SNATS shares (SNN) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $24.66 – a decrease of 3.41% over the previous week. Smith-and-Nephew SNATS employs 18,000 staff and has a trailing 12-month revenue of around $5.6 billion.

Our top picks for where to buy Smith-and-Nephew SNATS stock

Buy Smith-and-Nephew SNATS stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Smith-and-Nephew SNATS stock price (NYSE: SNN)

Use our graph to track the performance of SNN stocks over time.

Smith-and-Nephew SNATS shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$24.66
52-week range	$23.42 - $31.42
50-day moving average more info button	$26.49
200-day moving average more info button	$27.15
Wall St. target price	$32.55
PE ratio more info button	35.5571
Dividend yield more info button	$0.375 (3.01%)
Earnings per share (TTM) more info button	$0.70

Is it a good time to buy Smith-and-Nephew SNATS stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Smith-and-Nephew SNATS price performance over time

Historical closes compared with the close of $24.79 from 2024-12-19

1 week (2024-12-13)	-2.90%
1 month (2024-11-22)	-2.05%
3 months (2024-09-20)	-18.91%
6 months (2024-06-21)	-2.09%

1 year (2023-12-21)	-8.32%
2 years (2022-12-21)	-1.61%
3 years (2021-12-21)	30.6063
5 years (2019-12-20)	42.1746

Is Smith-and-Nephew SNATS stock undervalued or overvalued?

Valuing Smith-and-Nephew SNATS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Smith-and-Nephew SNATS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Smith-and-Nephew SNATS's P/E ratio

Smith-and-Nephew SNATS's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 36x. In other words, Smith-and-Nephew SNATS shares trade at around 36x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Smith-and-Nephew SNATS's PEG ratio

Smith-and-Nephew SNATS's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4131. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Smith-and-Nephew SNATS's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Smith-and-Nephew SNATS's EBITDA

Smith-and-Nephew SNATS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.

The EBITDA is a measure of a Smith-and-Nephew SNATS's overall financial performance and is widely used to measure a its profitability.

Smith-and-Nephew SNATS financials

Revenue TTM	$5.6 billion
Operating margin TTM	11.6%
Gross profit TTM	$3.7 billion
Return on assets TTM	4.51%
Return on equity TTM	5.84%
Profit margin	5.41%
Book value	$5.96
Market Capitalization more info button	$10.9 billion

TTM: trailing 12 months

Smith-and-Nephew SNATS share dividends

Dividend payout ratio: 107.45% of net profits

Recently Smith-and-Nephew SNATS has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Smith-and-Nephew SNATS shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Smith-and-Nephew SNATS's case, that would currently equate to about $0.375 per share.

Smith-and-Nephew SNATS's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Smith-and-Nephew SNATS's most recent dividend payout was on 7 November 2024. The latest dividend was paid out to all shareholders who bought their shares by 3 October 2024 (the "ex-dividend date").

Have Smith-and-Nephew SNATS's shares ever split?

Smith-and-Nephew SNATS's shares were split on a 2499:1000 basis on 14 October 2014 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 2499 shares. This wouldn't directly have changed the overall worth of your Smith-and-Nephew SNATS shares – just the quantity. However, indirectly, the new 60% lower share price could have impacted the market appetite for Smith-and-Nephew SNATS shares which in turn could have impacted Smith-and-Nephew SNATS's share price.

Smith-and-Nephew SNATS share price volatility

Over the last 12 months, Smith-and-Nephew SNATS's shares have ranged in value from as little as $23.4238 up to $31.4167. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Smith-and-Nephew SNATS's is 0.705. This would suggest that Smith-and-Nephew SNATS's shares are less volatile than average (for this exchange).

Smith-and-Nephew SNATS overview

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers.

Frequently asked questions

What percentage of Smith-and-Nephew SNATS is owned by insiders or institutions?
Currently 0.029% of Smith-and-Nephew SNATS shares are held by insiders and 7.576% by institutions. How many people work for Smith-and-Nephew SNATS?
Latest data suggests 18,000 work at Smith-and-Nephew SNATS. When does the fiscal year end for Smith-and-Nephew SNATS?
Smith-and-Nephew SNATS's fiscal year ends in December. Where is Smith-and-Nephew SNATS based?
Smith-and-Nephew SNATS's address is: Building 5, Watford, United Kingdom, WD18 8YE What is Smith-and-Nephew SNATS's ISIN number?
Smith-and-Nephew SNATS's international securities identification number is: US83175M2052 What is Smith-and-Nephew SNATS's CUSIP number?
Smith-and-Nephew SNATS's Committee on Uniform Securities Identification Procedures number is: 83175M106